The findings of the study lead the authors to a new mechanism that is regulated by the overexpression of BCL2A1 and the authors suggested that reversing this over-expression may increase the therapy success and BCL2A1 can be a novel target in refractory AML cases. Here, BCL2A1 is linked to acute myeloid leukemia.